X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
E.Merck: Shifting focus - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

E.Merck: Shifting focus

Sep 18, 2001

E.Merck (India), subsidiary of the German multinational Merck, reported a healthy topline performance for 2QFY02. While the company managed to log double digit topline growth operating margins were under pressure. The growth in sales is primarily due to an upward price revision in its vitamin brand Neurobion in June 2000.

(Rs m) 2QFY01 2QFY02 %Change FY01
Sales 791 881 11.3% 3,134
Other Income 9 38 346.3% 67
Expenditure 628 716 14.0% 2,582
Operating Profit (EBDIT) 163 165 1.0% 552
Operating Profit Margin (%) 20.6% 18.7% 17.6%
Interest 1 1 50.7% 23
Depreciation 15 24 59.9% 72
Profit before Tax 156 178 14.0% 524
Other Adjustments      
Tax 44 53 20.1% 139
Profit after Tax/(Loss) 112 125 11.7% 385
Net profit margin (%) 14.2% 14.2%   12.3%
No. of Shares (eoy) (m) 17 17   17
Diluted Earnings per share* 26.6 29.7   22.9
P/E (at current price) 9   12
(*- annualised)        

E. Merck is a market leader in vitamins and derives over 60% of its turnover from this segment. Three of its vitamin brands Evion, Neurobion and Polybion contribute almost 40% of the company’s turnover. During the first half of the current year the company re-introduced Neurobin with better marketing focus. However, the pharma division showed a sluggish growth of 3% mainly on account of competition from generic players. The slow growth in pharma division was more than compensated by a 20% growth in non-pharma division comprising laboratory and speciality chemicals.

One of the major threats to the company is high price volatility in Vitamin E due to fierce competition from Chinese and European suppliers. To overcome this concern, the company is evaluating various options like better utilisation of plant capacity and outsourcing of ingredients. Over the last couple of years the company has made a mark in other therapeutic segments such as cardiology, topical anti–inflammatory and dermatologicals while maintaining its mark in the vitamins segment. Apart from launching new products, the company also acquired Livogen brand from Glaxo India Ltd.

At the current market price of Rs 263, the stock trades at 12x times its FY01 earnings. Valuations going forward would depend on the success in new therapeutic areas, which the company has ventured into.


Equitymaster requests your view! Post a comment on "E.Merck: Shifting focus". Click here!

  

More Views on News

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

MERCK LTD Announces Quarterly Results (3QFY19); Net Profit Up 31.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, MERCK LTD has posted a net profit of Rs 135 m (up 31.3% YoY). Sales on the other hand came in at Rs 2 bn (down 32.8% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

3 Indian Stocks Replicating Amazon's Successful Strategy(The 5 Minute Wrapup)

May 10, 2019

The one critical element that has made Amazon a force to reckon with...

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

3 Stocks to Bet on to Become a 'Dividend Millionaire'(Profit Hunter)

May 14, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

A Simple Checklist for Picking Great Dividend Stocks(Profit Hunter)

May 9, 2019

A filtered, neat list of high-dividend stocks with all this dirty work already done for you.

The Bitter Pill that Will Lay the Foundation for Sensex 100,000(The 5 Minute Wrapup)

May 14, 2019

These companies will help the Sensex more than double from current levels.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

MERCK SHARE PRICE


May 21, 2019 (Close)

TRACK MERCK

COMPARE MERCK WITH

MARKET STATS